An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

Completed · Phase 2 · Has a placebo group

Conditions studied: Gastroesophageal Reflux

In brief

To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD

Key facts

Study ID

NCT00557401

Run by

XenoPort, Inc.

People needed

156

Starts

2007-11-01

Expected to finish

2008-09-01

Last updated by the study team

2021-02-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• History and documentation of GERD diagnosed by a gastroenterologist, with symptoms (heartburn and/or regurgitation) on ≥ 3 days during the week prior to screening and prior to randomization

You may not qualify if…

• Current or historical endoscopic evidence of erosive esophagitis LA Classification Grade B, C, or D

Where it is running

• MDS Pharma Services — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.